AstraZeneca sees higher 2022 sales, but COVID boost waning

AstraZeneca sees higher 2022 sales, but COVID boost waning

AstraZeneca forecast higher 2022 sales and raised its annual dividend for the first time in a decade, but warned that the boost from COVID-19 products would fall.


Share:

Comments

Comentarios de Facebook